tumor
antigen
recognition
cytolytic
lymphocyte
cytolytic
lymphocyte
ctls
primary
effector
cell
adaptive
immune
system
major
role
protecting
vast
array
disease
including
cancer
ctls
specifically
recognize
lyse
target
interaction
cell
receptor
tcrs
surface
lymphocyte
protein
fragment
peptide
presented
surface
target
cell
association
major
histocompatibility
complex
mhc
class
molecule
particular
ctl
interacts
target
cell
rapidly
divide
form
clonal
population
cell
identical
tcr
townsend
colleague
first
elucidated
molecular
basis
target
cell
recognition
ctls
showed
antigen
processed
inside
target
cell
peptide
presented
surface
association
mhc
class
molecule
discovery
suggested
possibility
using
short
synthetic
peptide
mimicking
naturally
processed
antigen
immunotherapeutic
drug
vaccine
short
synthetic
peptide
ideal
drug
development
relatively
low
cost
production
easy
storage
high
safety
however
peptide
mhc
allele
work
well
together
stimulate
ctls
clinical
use
either
patient
would
selected
treatment
based
mhc
type
would
necessary
make
multiple
peptide
cover
majority
mhc
class
allele
given
population
furthermore
boon
colleague
cloned
first
antigen
recognized
ctls
clear
antigen
recognized
ctls
human
possible
rationally
design
cancer
vaccine
however
long
list
le
antigen
generated
peptide
identified
far
either
normal
self
protein
aberrantly
expressed
cancer
adult
normal
tissue
antigen
also
expressed
certain
type
cancer
patient
show
spontaneous
cell
response
occasionally
high
level
specific
several
antigen
development
response
however
requires
large
tumor
load
occurs
late
disease
probably
efficient
destruction
tumor
cell
thus
central
objective
cancer
immunotherapy
efficiently
produce
ctls
earlier
phase
disease
heteroclitic
tumor
antigen
peptide
unfortunately
synthetic
peptide
including
corresponding
immunodominant
epitope
biggest
part
immune
response
tumor
antigen
seem
bind
mhc
class
molecule
medium
low
affinity
recognized
specific
cell
relatively
low
avidity
characteristic
likely
poor
immune
reaction
generated
peptide
one
strategy
improve
immune
reaction
make
called
heteroclitic
antigen
variant
improving
either
peptide
binding
mhc
recognition
tcrs
variant
increased
peptide
antigenicity
immunogenicity
solinger
colleague
first
describe
antigen
variant
producing
cell
response
stronger
elicited
parental
sequence
heteroclitic
tumor
antigen
peptide
showed
highly
improved
antigenicity
immunogenicity
preclinical
study
also
well
ctls
generated
parental
sequence
tested
clinical
trial
peptide
selected
trial
mostly
contained
substitution
anchoring
amino
acid
designed
increase
peptide
binding
mhc
molecule
minimally
changing
shape
epitope
study
lee
colleague
issue
plo
medicine
despite
careful
study
design
vaccination
peptide
resulted
recruitment
cell
bound
antigen
le
efficiently
lower
tumor
reactivity
endogenous
response
tumor
author
propose
decreased
affinity
ctls
could
high
antigen
density
synthetic
peptide
cell
alternative
explanation
however
synthetic
peptide
used
vaccination
simply
fail
faithfully
mimic
naturally
processed
antigen
figure
use
peptide
differ
resulting
natural
intracellular
processing
previously
given
rise
similar
problem
case
enormous
diversity
normal
tcr
repertoire
provides
molecular
explanation
observed
phenomenon
result
emphasize
difficult
translate
finding
spectacular
result
obtained
vaccination
tcr
transgenic
mouse
heteroclitic
peptide
application
normal
animal
human
conclusion
increasingly
clear
even
smallest
alteration
structure
mhc
peptide
complex
result
significant
change
tcrs
selected
vaccination
thus
manipulating
immune
cell
repertoire
vivo
use
heteroclitic
tumor
antigen
peptide
variant
could
harder
anticipated
field
move
rapidly
towards
use
new
vaccine
adjuvant
high
immunogenic
potential
reassessment
immunogenicity
natural
sequence
could
worthwhile
case
addition
careful
analysis
cell
clone
reported
lee
colleague
crucial
ascertain
quality
elicited
immune
response